Dr. Langer on the Future of Immunotherapy for Treatment of NSCLC

Corey J. Langer, MD
Published: Monday, Sep 09, 2019



Corey J. Langer, MD, director, thoracic oncology, Penn Medicine discusses the future of immunotherapy during a discussion about KEYNOTE-021 at the 2019 World Conference on Lung Cancer.

Moving forward with immunotherapy, Langer believes that oncologists will have answers to important ongoing questions. Who is more likely to benefit from immunotherapy? Which patients can receive immunotherapy in combination with chemotherapy and which patients should not get immunotherapy? To understand this, Langer suggest personalizing treatment and draw information from the profiles of those patients.

<<< 2019 World Conference on Lung Cancer


Corey J. Langer, MD, director, thoracic oncology, Penn Medicine discusses the future of immunotherapy during a discussion about KEYNOTE-021 at the 2019 World Conference on Lung Cancer.

Moving forward with immunotherapy, Langer believes that oncologists will have answers to important ongoing questions. Who is more likely to benefit from immunotherapy? Which patients can receive immunotherapy in combination with chemotherapy and which patients should not get immunotherapy? To understand this, Langer suggest personalizing treatment and draw information from the profiles of those patients.

<<< 2019 World Conference on Lung Cancer

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x